Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76.

Hassan NJ, Simmonds SJ, Clarkson NG, Hanrahan S, Puklavec MJ, Bomb M, Barclay AN, Brown MH.

Mol Cell Biol. 2006 Sep;26(17):6727-38. Erratum in: Mol Cell Biol. 2009 Jun;29(12):3452.

2.

Frontline: Optimal T cell activation requires the engagement of CD6 and CD166.

Hassan NJ, Barclay AN, Brown MH.

Eur J Immunol. 2004 Apr;34(4):930-40.

3.

Relevance of CD6-mediated interactions in T cell activation and proliferation.

Gimferrer I, Calvo M, Mittelbrunn M, Farnós M, Sarrias MR, Enrich C, Vives J, Sánchez-Madrid F, Lozano F.

J Immunol. 2004 Aug 15;173(4):2262-70.

4.

Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor.

Ibáñez A, Sarrias MR, Farnós M, Gimferrer I, Serra-Pagès C, Vives J, Lozano F.

J Immunol. 2006 Jul 15;177(2):1152-9.

5.

CD6 attenuates early and late signaling events, setting thresholds for T-cell activation.

Oliveira MI, Gonçalves CM, Pinto M, Fabre S, Santos AM, Lee SF, Castro MA, Nunes RJ, Barbosa RR, Parnes JR, Yu C, Davis SJ, Moreira A, Bismuth G, Carmo AM.

Eur J Immunol. 2012 Jan;42(1):195-205. doi: 10.1002/eji.201040528. Epub 2011 Nov 28.

6.

CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

Nair P, Melarkode R, Rajkumar D, Montero E.

Clin Exp Immunol. 2010 Oct;162(1):116-30. doi: 10.1111/j.1365-2249.2010.04235.x. Epub 2010 Aug 19.

7.

Human CD6 possesses a large, alternatively spliced cytoplasmic domain.

Robinson WH, Neuman de Vegvar HE, Prohaska SS, Rhee JW, Parnes JR.

Eur J Immunol. 1995 Oct;25(10):2765-9.

PMID:
7589069
8.

A 10-aa-long sequence in SLP-76 upstream of the Gads binding site is essential for T cell development and function.

Kumar L, Feske S, Rao A, Geha RS.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19063-8. Epub 2005 Dec 14.

9.

CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes.

Singer NG, Mitra R, Lialios F, Richardson BC, Marks RM, Pesando JM, Fox DA, Nickoloff BJ.

Immunol Lett. 1997 Jun;58(1):9-14.

PMID:
9436462
10.

Docking protein Gab2 is phosphorylated by ZAP-70 and negatively regulates T cell receptor signaling by recruitment of inhibitory molecules.

Yamasaki S, Nishida K, Hibi M, Sakuma M, Shiina R, Takeuchi A, Ohnishi H, Hirano T, Saito T.

J Biol Chem. 2001 Nov 30;276(48):45175-83. Epub 2001 Sep 25.

11.

Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation.

Osorio LM, Ordonez C, Garcia CA, Jondal M, Chow SC.

Cell Immunol. 1995 Nov;166(1):44-52.

PMID:
7585980
12.

Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.

Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Guirola O, Chinea G, Montero E.

Hybridoma (Larchmt). 2008 Aug;27(4):291-301. doi: 10.1089/hyb.2008.0007.

PMID:
18707547
13.

Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction.

Starling GC, Whitney GS, Siadak AW, Llewellyn MB, Bowen MA, Farr AG, Aruffo AA.

Eur J Immunol. 1996 Apr;26(4):738-46.

PMID:
8625962
14.

The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells.

Gimferrer I, Farnós M, Calvo M, Mittelbrunn M, Enrich C, Sánchez-Madrid F, Vives J, Lozano F.

J Biol Chem. 2003 Mar 7;278(10):8564-71. Epub 2002 Dec 8.

15.

OX52 is the rat homologue of CD6: evidence for an effector function in the regulation of CD5 phosphorylation.

Castro MA, Nunes RJ, Oliveira MI, Tavares PA, Simões C, Parnes JR, Moreira A, Carmo AM.

J Leukoc Biol. 2003 Jan;73(1):183-90.

16.

Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues.

Saifullah MK, Fox DA, Sarkar S, Abidi SM, Endres J, Piktel J, Haqqi TM, Singer NG.

J Immunol. 2004 Nov 15;173(10):6125-33.

18.

Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1.

van Seventer GA, Newman W, Shimizu Y, Nutman TB, Tanaka Y, Horgan KJ, Gopal TV, Ennis E, O'Sullivan D, Grey H, et al.

J Exp Med. 1991 Oct 1;174(4):901-13.

19.

Mutational analysis of the CD6 ligand binding domain.

Skonier JE, Bodian DL, Emswiler J, Bowen MA, Aruffo A, Bajorath J.

Protein Eng. 1997 Aug;10(8):943-7.

20.

CD6 as a therapeutic target in autoimmune diseases: successes and challenges.

Pinto M, Carmo AM.

BioDrugs. 2013 Jun;27(3):191-202. doi: 10.1007/s40259-013-0027-4. Review.

PMID:
23568178
Items per page

Supplemental Content

Write to the Help Desk